These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 29040190)

  • 1. Novel Therapeutics for Ovarian Cancer: The 11th Biennial Rivkin Center Ovarian Cancer Research Symposium.
    Johnson N; Liao JB
    Int J Gynecol Cancer; 2017 Nov; 27(9S Suppl 5):S14-S19. PubMed ID: 29040190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel therapeutics: response and resistance in ovarian cancer.
    Zamarin D
    Int J Gynecol Cancer; 2019 Aug; 29(Suppl 2):s16-s21. PubMed ID: 31462544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meeting Report From the 2016 11th Biennial Ovarian Cancer Research Symposium: Mechanisms of Initiation and Progression of Ovarian Cancers.
    Chien J; Mehta G
    Int J Gynecol Cancer; 2017 Nov; 27(9S Suppl 5):S10-S13. PubMed ID: 29278599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomics and molecular mechanisms of high grade serous ovarian cancer: the 12th Biennial Rivkin Center Ovarian Cancer Research Symposium.
    Rankin EB
    Int J Gynecol Cancer; 2019 Aug; 29(Suppl 2):s7-s11. PubMed ID: 31462542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor Microenvironment and Models of Ovarian Cancer: The 11th Biennial Rivkin Center Ovarian Cancer Research Symposium.
    McLean K; Mehta G
    Int J Gynecol Cancer; 2017 Nov; 27(9S Suppl 5):S2-S9. PubMed ID: 29049091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Research Summaries: The 11th Biennial Rivkin Center Ovarian Cancer Research Symposium.
    Armstrong DK
    Int J Gynecol Cancer; 2017 Nov; 27(9S Suppl 5):S1. PubMed ID: 29278598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Introduction: the 12th Biennial Rivkin Center Ovarian Cancer Research Symposium.
    Maihle NJ; Levine DA; Dhillon K; Armstrong DK
    Int J Gynecol Cancer; 2019 Aug; 29(Suppl 2):s1. PubMed ID: 31462540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The current status of PARP inhibitors in ovarian cancer.
    McLachlan J; George A; Banerjee S
    Tumori; 2016 Oct; 102(5):433-440. PubMed ID: 27716873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor microenvironment and immunology of ovarian cancer: 12th Biennial Rivkin Center Ovarian Cancer Research Symposium.
    Mitra AK; Yang-Hartwich Y
    Int J Gynecol Cancer; 2019 Aug; 29(Suppl 2):s12-s15. PubMed ID: 31462543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ovarian Cancer Prevention, Screening, and Early Detection: Report From the 11th Biennial Ovarian Cancer Research Symposium.
    Chien J; Poole EM
    Int J Gynecol Cancer; 2017 Nov; 27(9S Suppl 5):S20-S22. PubMed ID: 29278600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
    Parkes EE; Kennedy RD
    Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer.
    Higuchi T; Flies DB; Marjon NA; Mantia-Smaldone G; Ronner L; Gimotty PA; Adams SF
    Cancer Immunol Res; 2015 Nov; 3(11):1257-68. PubMed ID: 26138335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meeting report from the 2018 12th Biennial Ovarian Cancer Research Symposium detection and prevention of ovarian cancer.
    Xian W; George S
    Int J Gynecol Cancer; 2019 Aug; 29(Suppl 2):s2-s6. PubMed ID: 31462541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
    Liu FW; Tewari KS
    Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel poly-ADP-ribose polymerase inhibitor combination strategies in ovarian cancer.
    McCann KE
    Curr Opin Obstet Gynecol; 2018 Feb; 30(1):7-16. PubMed ID: 29251678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PARP inhibitors: Clinical utility and possibilities of overcoming resistance.
    Bitler BG; Watson ZL; Wheeler LJ; Behbakht K
    Gynecol Oncol; 2017 Dec; 147(3):695-704. PubMed ID: 29037806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA damage response as a therapeutic target in gynecological cancers.
    Leary A; Auguste A; Mesnage S
    Curr Opin Oncol; 2016 Sep; 28(5):404-11. PubMed ID: 27455135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 1: olaparib.
    Miller RE; Ledermann JA
    Clin Adv Hematol Oncol; 2016 Aug; 14(8):619-27. PubMed ID: 27487106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advancements of antiangiogenic combination therapies in ovarian cancer.
    An D; Banerjee S; Lee JM
    Cancer Treat Rev; 2021 Jul; 98():102224. PubMed ID: 34051628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Abnormalities of DNA repair and gynecological cancers].
    Auguste A; Leary A
    Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.